title: How can we improve the treatment of bone metastases further?
abstract: Bone is one of the most frequent organs to be affected by metastatic cancer and causes more morbidity than any other metastatic site. Bisphosphonate treatment provides an organ-specific treatment which is relevant to most if not all tumour types involving bone. Bisphosphonates, particularly the potent agent pamidronate (Aredia), will relieve metastatic bone pain with a consequent improvement in quality of life in approximately 50% of patients. Long-term bisphosphonate treatment clearly reduces skeletal morbidity rates in multiple myeloma and breast cancer.
authors.affiliation: YCR Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
authors.forename: R E
authors.initials: RE
authors.lastname: Coleman
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000473:pathology; D004164:Diphosphonates / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000009:adverse effects; D005260:Female; D005544:Forecasting; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy; D010014:Osteolysis / Q000188:drug therapy; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000473:pathology; D011788:Quality of Life; D011867:Radioisotope Teletherapy; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012493:Samarium / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D004965:Estrogen Antagonists; D012493:Samarium